We are analyzing https://link.springer.com/article/10.1007/s40268-023-00417-7.

Title:
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease | Drugs in R&D
Description:
Adult-onset Still’s disease (AOSD) is an idiopathic systemic inflammatory disease of unknown aetiology. Some patients exhibit resistance to conventional treatment during long-term therapy. Janus kinase inhibitors (JAKinibs) may contribute to the improvement in AOSD symptoms via the JAK–signal transducer and activator of transcription (STAT) pathway. We aimed to explore the efficacy and safety of baricitinib in patients with refractory AOSD. Patients were enrolled if they fulfilled the Yamaguchi AOSD classification criteria in China between 2020 and 2022. All patients were recognized as having refractory AOSD and were treated with oral baricitinib at a dosage of 4 mg once daily. A systemic score and prednisone dosage were used to evaluate the efficacy of baricitinib at months 1, 3, and 6 and at the last follow-up visit. The safety profiles were recorded and analysed at every assessment. Seven female patients with refractory AOSD received baricitinib. The median age was 31 (IQR 10) years. Treatment was terminated in one patient due to progressive macrophage activation syndrome (MAS). Others continued baricitinib treatment until the last assessment. The systemic score decreased significantly at 3 months (p = 0.0216), 6 months (p = 0.0007), and the last follow-up visit (p = 0.0007) compared with baseline. One month after the initiation of baricitinib, the rates of improvement in fever, rash, sore throat, and myalgia symptoms were 71.4% (5/7), 40% (2/5), 80% (4/5), and 66.7% (2/3), respectively. Five patients remained symptom-free at the last follow-up visit. In most patients, their laboratory values had returned to normal by the last follow-up visit. A significant reduction in the levels of C-reactive protein (CRP) (p = 0.0165) and ferritin (p = 0.0047) was observed at the last visit compared with baseline. The daily prednisolone dosage significantly decreased from 35.7 ± 15.1 mg/day at baseline to 8.8 ± 4.4 mg/day by month 6 (p = 0.0256), and it was 5.8 ± 4.7 mg/day at the last assessment (p = 0.0030). Leukopenia due to MAS was noted in one patient. Except for mild abnormalities in lipid parameters, no other severe adverse events occurred during follow-up. Our findings suggest that baricitinib therapy could provide rapid and durable clinical and laboratory improvement in patients with refractory AOSD. Treatment seemed to be well tolerated by these patients. The long-term efficacy and safety of baricitinib therapy for AOSD should be assessed further in prospective controlled clinical trials in the future. Trial registration number (TRN): ChiCTR2200061599. Date of registration: 29 June 2022 (retrospectively registered).
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

patients, baricitinib, aosd, treatment, pubmed, disease, google, scholar, stills, patient, clinical, visit, month, refractory, adultonset, study, therapy, mas, cas, followup, iqr, efficacy, systemic, observed, dosage, months, baseline, arthritis, crp, data, longterm, safety, score, initiation, inflammatory, decreased, mgday, tcz, fig, rheumatol, article, symptoms, assessment, due, syndrome, laboratory, ferritin, adverse, events, cholesterol,

Topics {✒️}

wei wei & xin li ifn-γ-mediated signalling pathways low-density lipoprotein cholesterol nonsteroidal anti-inflammatory drugs high-density lipoprotein cholesterol targeted therapies median plasma d-dimer level potentially life-threatening complications erythrocyte sedimentation rate article download pdf differential diagnostic investigations phase 3 comfort steroid-resistant acute gvhd treat auto-inflammatory diseases receptor monoclonal antibody crp c-reactive protein low-dose corticosteroid treatment clinical aosd-related characteristics systematic literature review patients remained symptom-free aosd-related mas exacerbation full access bmc res notes biological agent therapies long-term clinical effects biological-resistant adult-onset selective jak1/jak2 inhibitor gonzález-gay ma severe rheumatoid arthritis privacy choices/manage cookies c-reactive protein treating refractory adult-onset janus kinase inhibitors macrophage activation syndrome macrophage-activation syndrome high-level serum ferritin related subjects life-threatening complications disseminated intravascular coagulation tumour necrosis factor kolmogorov–smirnov test kruskal–wallis test refractory rheumatoid arthritis fibrinogen equivalent units tianjin health commission plasma d-dimer severe adverse events cytokine-targeting biologics macrophage inhibitory factors pharmacodynamic cytokine signalling

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
         description:Adult-onset Still’s disease (AOSD) is an idiopathic systemic inflammatory disease of unknown aetiology. Some patients exhibit resistance to conventional treatment during long-term therapy. Janus kinase inhibitors (JAKinibs) may contribute to the improvement in AOSD symptoms via the JAK–signal transducer and activator of transcription (STAT) pathway. We aimed to explore the efficacy and safety of baricitinib in patients with refractory AOSD. Patients were enrolled if they fulfilled the Yamaguchi AOSD classification criteria in China between 2020 and 2022. All patients were recognized as having refractory AOSD and were treated with oral baricitinib at a dosage of 4 mg once daily. A systemic score and prednisone dosage were used to evaluate the efficacy of baricitinib at months 1, 3, and 6 and at the last follow-up visit. The safety profiles were recorded and analysed at every assessment. Seven female patients with refractory AOSD received baricitinib. The median age was 31 (IQR 10) years. Treatment was terminated in one patient due to progressive macrophage activation syndrome (MAS). Others continued baricitinib treatment until the last assessment. The systemic score decreased significantly at 3 months (p = 0.0216), 6 months (p = 0.0007), and the last follow-up visit (p = 0.0007) compared with baseline. One month after the initiation of baricitinib, the rates of improvement in fever, rash, sore throat, and myalgia symptoms were 71.4% (5/7), 40% (2/5), 80% (4/5), and 66.7% (2/3), respectively. Five patients remained symptom-free at the last follow-up visit. In most patients, their laboratory values had returned to normal by the last follow-up visit. A significant reduction in the levels of C-reactive protein (CRP) (p = 0.0165) and ferritin (p = 0.0047) was observed at the last visit compared with baseline. The daily prednisolone dosage significantly decreased from 35.7 ± 15.1 mg/day at baseline to 8.8 ± 4.4 mg/day by month 6 (p = 0.0256), and it was 5.8 ± 4.7 mg/day at the last assessment (p = 0.0030). Leukopenia due to MAS was noted in one patient. Except for mild abnormalities in lipid parameters, no other severe adverse events occurred during follow-up. Our findings suggest that baricitinib therapy could provide rapid and durable clinical and laboratory improvement in patients with refractory AOSD. Treatment seemed to be well tolerated by these patients. The long-term efficacy and safety of baricitinib therapy for AOSD should be assessed further in prospective controlled clinical trials in the future. Trial registration number (TRN): ChiCTR2200061599. Date of registration: 29 June 2022 (retrospectively registered).
         datePublished:2023-04-03T00:00:00Z
         dateModified:2023-04-03T00:00:00Z
         pageStart:109
         pageEnd:120
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s40268-023-00417-7
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig4_HTML.png
         isPartOf:
            name:Drugs in R&D
            issn:
               1179-6901
               1174-5886
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ziyi Sun
               affiliation:
                     name:Tianjin Medical University General Hospital
                     address:
                        name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                     address:
                        name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rongqi Li
               affiliation:
                     name:Tianjin Medical University General Hospital
                     address:
                        name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                     address:
                        name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yingai Wang
               affiliation:
                     name:Tianjin Medical University General Hospital
                     address:
                        name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                     address:
                        name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Feng Han
               affiliation:
                     name:Tianjin Medical University General Hospital
                     address:
                        name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                     address:
                        name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wei Wei
               affiliation:
                     name:Tianjin Medical University General Hospital
                     address:
                        name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                     address:
                        name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xin Li
               affiliation:
                     name:Tianjin Medical University General Hospital
                     address:
                        name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                     address:
                        name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
      description:Adult-onset Still’s disease (AOSD) is an idiopathic systemic inflammatory disease of unknown aetiology. Some patients exhibit resistance to conventional treatment during long-term therapy. Janus kinase inhibitors (JAKinibs) may contribute to the improvement in AOSD symptoms via the JAK–signal transducer and activator of transcription (STAT) pathway. We aimed to explore the efficacy and safety of baricitinib in patients with refractory AOSD. Patients were enrolled if they fulfilled the Yamaguchi AOSD classification criteria in China between 2020 and 2022. All patients were recognized as having refractory AOSD and were treated with oral baricitinib at a dosage of 4 mg once daily. A systemic score and prednisone dosage were used to evaluate the efficacy of baricitinib at months 1, 3, and 6 and at the last follow-up visit. The safety profiles were recorded and analysed at every assessment. Seven female patients with refractory AOSD received baricitinib. The median age was 31 (IQR 10) years. Treatment was terminated in one patient due to progressive macrophage activation syndrome (MAS). Others continued baricitinib treatment until the last assessment. The systemic score decreased significantly at 3 months (p = 0.0216), 6 months (p = 0.0007), and the last follow-up visit (p = 0.0007) compared with baseline. One month after the initiation of baricitinib, the rates of improvement in fever, rash, sore throat, and myalgia symptoms were 71.4% (5/7), 40% (2/5), 80% (4/5), and 66.7% (2/3), respectively. Five patients remained symptom-free at the last follow-up visit. In most patients, their laboratory values had returned to normal by the last follow-up visit. A significant reduction in the levels of C-reactive protein (CRP) (p = 0.0165) and ferritin (p = 0.0047) was observed at the last visit compared with baseline. The daily prednisolone dosage significantly decreased from 35.7 ± 15.1 mg/day at baseline to 8.8 ± 4.4 mg/day by month 6 (p = 0.0256), and it was 5.8 ± 4.7 mg/day at the last assessment (p = 0.0030). Leukopenia due to MAS was noted in one patient. Except for mild abnormalities in lipid parameters, no other severe adverse events occurred during follow-up. Our findings suggest that baricitinib therapy could provide rapid and durable clinical and laboratory improvement in patients with refractory AOSD. Treatment seemed to be well tolerated by these patients. The long-term efficacy and safety of baricitinib therapy for AOSD should be assessed further in prospective controlled clinical trials in the future. Trial registration number (TRN): ChiCTR2200061599. Date of registration: 29 June 2022 (retrospectively registered).
      datePublished:2023-04-03T00:00:00Z
      dateModified:2023-04-03T00:00:00Z
      pageStart:109
      pageEnd:120
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s40268-023-00417-7
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40268-023-00417-7/MediaObjects/40268_2023_417_Fig4_HTML.png
      isPartOf:
         name:Drugs in R&D
         issn:
            1179-6901
            1174-5886
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ziyi Sun
            affiliation:
                  name:Tianjin Medical University General Hospital
                  address:
                     name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                  address:
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rongqi Li
            affiliation:
                  name:Tianjin Medical University General Hospital
                  address:
                     name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                  address:
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yingai Wang
            affiliation:
                  name:Tianjin Medical University General Hospital
                  address:
                     name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                  address:
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Feng Han
            affiliation:
                  name:Tianjin Medical University General Hospital
                  address:
                     name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                  address:
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wei Wei
            affiliation:
                  name:Tianjin Medical University General Hospital
                  address:
                     name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                  address:
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xin Li
            affiliation:
                  name:Tianjin Medical University General Hospital
                  address:
                     name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
                  address:
                     name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Drugs in R&D
      issn:
         1179-6901
         1174-5886
      volumeNumber:23
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Tianjin Medical University General Hospital
      address:
         name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
      address:
         name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Medical University General Hospital
      address:
         name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
      address:
         name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Medical University General Hospital
      address:
         name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
      address:
         name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Medical University General Hospital
      address:
         name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
      address:
         name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Medical University General Hospital
      address:
         name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
      address:
         name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Medical University General Hospital
      address:
         name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
         type:PostalAddress
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
      address:
         name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ziyi Sun
      affiliation:
            name:Tianjin Medical University General Hospital
            address:
               name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
            address:
               name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Rongqi Li
      affiliation:
            name:Tianjin Medical University General Hospital
            address:
               name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
            address:
               name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Yingai Wang
      affiliation:
            name:Tianjin Medical University General Hospital
            address:
               name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
            address:
               name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Feng Han
      affiliation:
            name:Tianjin Medical University General Hospital
            address:
               name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
            address:
               name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Wei Wei
      affiliation:
            name:Tianjin Medical University General Hospital
            address:
               name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
            address:
               name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Xin Li
      affiliation:
            name:Tianjin Medical University General Hospital
            address:
               name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases
            address:
               name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
      name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
      name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
      name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
      name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China
      name:Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
      name:Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin, People’s Republic of China

External Links {🔗}(130)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.68s.

LINK . SPRINGER . COM {}